Cargando…
Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explo...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241724/ https://www.ncbi.nlm.nih.gov/pubmed/34239361 http://dx.doi.org/10.7150/ijbs.57810 |
_version_ | 1783715474187485184 |
---|---|
author | Sun, Fang Mu, Chenglin Kwok, Hang Fai Xu, Jiyuan Wu, Yingliang Liu, Wanhong Sabatier, Jean-Marc Annweiler, Cédric Li, Xugang Cao, Zhijian Xie, Yingqiu |
author_facet | Sun, Fang Mu, Chenglin Kwok, Hang Fai Xu, Jiyuan Wu, Yingliang Liu, Wanhong Sabatier, Jean-Marc Annweiler, Cédric Li, Xugang Cao, Zhijian Xie, Yingqiu |
author_sort | Sun, Fang |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era. |
format | Online Article Text |
id | pubmed-8241724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-82417242021-07-07 Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19 Sun, Fang Mu, Chenglin Kwok, Hang Fai Xu, Jiyuan Wu, Yingliang Liu, Wanhong Sabatier, Jean-Marc Annweiler, Cédric Li, Xugang Cao, Zhijian Xie, Yingqiu Int J Biol Sci Research Paper Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era. Ivyspring International Publisher 2021-06-11 /pmc/articles/PMC8241724/ /pubmed/34239361 http://dx.doi.org/10.7150/ijbs.57810 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Sun, Fang Mu, Chenglin Kwok, Hang Fai Xu, Jiyuan Wu, Yingliang Liu, Wanhong Sabatier, Jean-Marc Annweiler, Cédric Li, Xugang Cao, Zhijian Xie, Yingqiu Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19 |
title | Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19 |
title_full | Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19 |
title_fullStr | Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19 |
title_full_unstemmed | Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19 |
title_short | Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19 |
title_sort | capivasertib restricts sars-cov-2 cellular entry: a potential clinical application for covid-19 |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241724/ https://www.ncbi.nlm.nih.gov/pubmed/34239361 http://dx.doi.org/10.7150/ijbs.57810 |
work_keys_str_mv | AT sunfang capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 AT muchenglin capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 AT kwokhangfai capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 AT xujiyuan capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 AT wuyingliang capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 AT liuwanhong capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 AT sabatierjeanmarc capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 AT annweilercedric capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 AT lixugang capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 AT caozhijian capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 AT xieyingqiu capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19 |